Skip to main content
SpringerLink
Log in

Schwerpunkt "Zukunft der Immuncheckpointinhibition"

Aktivierung von Immunzellrezeptoren statt Checkpointblockade

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64

  2. Cho BC et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781-92

  3. Curigliano G et al. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021;27(13):3620-9

  4. Landsberg J et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412-6

  5. Glodde N et al. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017;47(4):789-802.e9

  6. Effern M et al. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity. 2020;53(3):564-580.e9

  7. Klümper N et al. C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma. Clin Transl Immunology. 2021;10(12):e1358

  8. Hahn AW et al. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9(8):681-92

  9. Mayes PA et al. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018;17(7):509-27

  10. Smith-Garvin JE et al. T Cell Activation. Annu Rev Immunol. 2009;27(1):591-619

  11. Schwartz JCD et al. Structural mechanisms of costimulation. Nat Immunol. 2002;3(5):427-34

  12. Zhang Q, Vignali DAA. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity. 2016;44(5):1034-51

  13. Suntharalingam G et al. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med. 2006;355(10):1018-28

  14. Hünig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol. 2012;12(5):317-8

  15. French RR et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5(5):548-53

  16. Barlesi F et al. 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. J Immunother Cancer. 2020; https://doi.org/kmw5

  17. Padrón LJ et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167-77

  18. Djureinovic D et al. Agonistic CD40 Antibodies in Cancer Treatment. Cancers (Basel). 2021;13(6):1302

  19. Kjaergaard J et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19):5514-21

  20. Postel-Vinay S et al. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer. 2023;11(3):e005301

  21. Yadav R, Redmond WL. Current Clinical Trial Landscape of OX40 Agonists. Curr Oncol Rep. 2022;24(7):951-60

  22. Melero I et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682-5

  23. Chu DT et al. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int J Mol Sci. 2019;20(8):1822

  24. Segal NH et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2017;23(8):1929-36

  25. Claus C et al. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs. 2023;15(1):2167189

  26. Chester C et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49-57

  27. Labrijn AF et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585-608

  28. Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-65

  29. Kantarjian H et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-47

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle Onkologie, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland

    Tobias Bald &  Nicole Glodde

Authors
  1. Tobias Bald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole Glodde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bald, T., Glodde, N. Aktivierung von Immunzellrezeptoren statt Checkpointblockade. InFo Hämatol Onkol 26, 10–15 (2023). https://doi.org/10.1007/s15004-023-0035-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-023-0035-6

Search

Navigation